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Summary
Parkinson’s disease (PD) is a fatal, incurable,
neurodegenerative disease that affects
approximately 4 million people worldwide. In this
disease, dopaminergic neurons selectively die
causing symptoms of postural rigidity, slowed
motor movement, and resting tremors.  Recently,
the α -synuclein gene has been linked to both
familial and sporadic forms of PD.  α-Synuclein
protein misfolds, aggregates and ultimately leads to
cell death in dopaminergic neurons, but molecular
mechanisms that cause misfolding and cell death
are not fully understood.  α - S y n u c l e i n
overexpression causes PD-like pathology and
symptoms in fruit flies and mice (two common
model organisms).  Till date, no yeast model for PD
has been reported. Given the present ability to
genetically and biochemically manipulate yeast, we
believe that this model system will facilitate
understanding of α -synuclein misfolding and
aggregation processes.  This senior thesis project
has four aims: to express α-synuclein in yeast,
characterize its effect on yeast growth and
metabolism, describe protein solubility, and
characterize protein stability in yeast. Wild type and
three α-synuclein mutant genes were put into yeast.
Both wild type and mutant α-synuclein protein were
expressed to similar levels in yeast, but all forms
appear larger in size than predicted on protein gels
suggesting added structural modifications.  Neither
wild type nor mutant α -synuclein expression
grossly affected cell growth, but some mutants may
have affected adenine metabolism.  While all forms
of α-synuclein were purified from yeast under
native and denaturing conditions, some α-synuclein
was resistant to solubilization, and mutants more
frequently showed multiple monomeric forms.
Also, mutants appeared more stable in yeast
compared to wild type α -synuclein.  We have
developed one of the first yeast models that
recapitulate protein misfolding and aggregation in
PD.  In the future, this model will allow us to
genetically dissect factors that accelerate or inhibit
α- synuclein misfolding.
Introduction
The Human Brain and Neurodegenerative Illnesses
The human brain tightly regulates our perceptions of
the external environment as well as our physical and
emotional behavior. Through its billions of cells it
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houses our memories and our ability to learn, and it
mysteriously underlies our human consciousness.
Irreparable cell death in this powerful organ loosens its
regulation of physiological processes, and distorts
perceptions of reality.  The effects of a diseased brain
can permeate the entire body and disrupt the balance
of the human mind.
Neurodegenerative diseases (NDDs),
including Alzheimer’s disease, prion diseases,
amyotrophic lateral sclerosis, and Parkinson’s disease,
are a diverse family of chronic, progressive illnesses of
the nervous system with no known corrective
treatments (Price et al., 1998).  NDDs can be sporadic
(most cases), genetic, or infectious (Shoulson, 1998).
NDDs span all cultures and affect millions of people
(Shoulson, 1998).  Because of their high prevalence,
morbidity and mortality, NDDs raise significant medical
and sociological concerns.
Neuropathologically, NDDs are characterized
by cellular abnormalities in specific regions of the
central nervous system.  The affected cells are discrete
for each NDD, and each affected area confers a clinical
phenotype of that particular illness (Sherman &
Goldberg, 2001).  For example, Alzheimer’s disease,
the most common NDD, is associated with the atrophy
of brain regions and cells essential for memory and
cognition, including the neocortex, amygdala, and
hippocampus (Morrison et al., 1997).  Cell death in
these regions causes the familiar symptoms of memory
loss, disorientation, deficits in problem solving and
dementia (Morrison et al., 1997).  Similarly, the
behavioral symptoms of all other NDDs are caused by
specific neuronal death and weakened signaling
pathways.  Though the affected regions of the brain
have been mapped in most NDDs, the cellular
mechanisms that are involved in the initiation and
progression of these illnesses are not fully understood
(Sherman & Goldberg, 2001).
At the molecular level, however, a common
pathological theme has emerged: each known NDD is
associated with the aggregation of one or more specific
misfolded proteins within the nervous system (Sherman
& Goldberg, 2001).  All proteins must exist in a specific
shape to be biologically active.  While a protein’s shape
is governed by its amino acid structure, chaperone
proteins often assist the folding processes within the
dense cellular environment.  Chaperones facilitate
correct protein folding, maintain protein shape, and
restore proper structure to misfolded proteins (Horwich
et al., 1999).  If the correct shape cannot be restored or
if a protein’s shape is damaged over time, the protein is
tagged and degraded by the ubiquitin/proteosome
complex (Hochstrasser, 1996).  Sometimes, proteins
acquire a misfolded shape that cannot be corrected by
chaperones or removed efficiently by the degradation
pathway.  Aggregation of these misfolded proteins is
presumed to cause neuronal death, underlying several
NDDs (Taylor et al., 2002).   This thesis focuses
specifically on PD and the protein misfolding processes
associated with its neurpathology, as detailed next.
Parkinson’s disease
This NDD affects 4 million people worldwide (Masliah et al., 2001).    Its prevalence and cost  to  human  society
Motor Cortex
Substantia Nigra
x
V
Lower Motor Neuron
Muscle
PD
Basal Ganglia
Sensory  
Information
Voluntary Movement
Upper Motor
Neuron
Spinal Cord
Figure 1. Neuronal Structures Regulating Voluntary Movement: Role of Basal Ganglia
Neurons in the basal ganglia integrate sensory and homeostatic information and signal the upper motor neurons in the frontal cortex to gate
the initiation and termination of voluntary movement.  These neurons pass the movement information to the lower motor neurons in the
spinal cord, which innervate the muscles.  The substantia nigra is an important group of cells in the basal ganglia.  Cell death in the
substantia nigra reduces the quality and precision of signaling to the motor cortex, resulting in hypokinesia (slowed movement).  This is a
schematic representation, not designed to reflect all anatomical connections.
necessitates research into its molecular basis and
possible treatments.  Behavioral symptoms of
Parkinson’s disease include muscular rigidity, postural
instability, resting tremors, difficulties in initiating
movement, and slowed motor function (Parkinson,
1817). The basal ganglia integrate sensory information
and send signals to the primary motor cortex to regulate
the initiation of voluntary movement (Goedbert, 2001).
PD patients show severely reduced levels of the
neurotransmitter dopamine (Ehringer & Hornykiewicz,
1960) and significant loss of dopamine producing cells
in the substantia nigra, a midbrain structure within the
basal ganglia (figure 1; Goedbert, 2001). The loss of
substantia nigra neurons reduces signaling from the
basal ganglia to the motor cortex, decreasing overall
voluntary movement (Ehringer & Hornykiewicz, 1960).
Two Forms of PD
Sporadic PD: This dominant form of PD accounts for
95% of all cases (Goedbert, 2001), and affects one
percent of all people over 60 years of age (Barbosa et
al., 1997).  Sporadic PD is linked to the loss of cellular
processes during aging or exposure to poorly
understood environmental conditions (Betarbet et al.,
2001), including exposure to contaminated well water,
herbicides, and industrial chemicals (figure 2; Olanow &
Tatton, 1999).  According to one hypothesis, these
toxins may randomly mutate genes in dopamine-
producing cells.  Over a lifetime, somatic mutations in
substantia nigra neurons may accumulate to
significantly reduce dopamine levels and cause PD
symptoms (Seidler et al., 1996).  An infectious agent
may also cause sporadic PD.  Patients suffering from
the infectious NDD encephalitis lethargica show PD-like
symptoms (Takahashi & Yamada, 1999).  Patients
show neuronal damage confined to the substantia
nigra, where the neurovirulent influenza A virus is also
localized.  A variety of other bacterial and viral agents
have been reported to induce encephalitis and
subsequent PD-like symptoms (Kohbata & Shimokawa,
1993), but repeated attempts to find an infectious agent
consistent with authentic PD development have failed
(Stoessl, 1999).
In the lab, animals have been designed to
recapitulate PD pathology by exposing them to drugs
and toxins.   Rat models of sporadic PD include
intravenous exposure to rotenone, a common pesticide
(Betarbet et al., 2001), and 1-methyl-4-phenyl-1-2-3-6-
tetrahydropyridine (MPTP; Singer et al., 1987), a
byproduct of methamphetamine synthesis.  Both
molecules are inhibitors of mitochondrial complex I in
rats (Betarbet et al., 2001, Singer et al, 1987), which
plays an important role in ATP synthesis, and protects
the cell against reactive oxygen species (ROS).  When
complex I is inactivated, cellular concentrations of ROS
increase, causing protein and DNA damage (Langston
et al., 1983; Singer et al. 1987).  In rats, chronic
exposure to rotenone and MPTP causes the selective
degeneration of dopaminergic neurons, formation of
inclusions in substantia nigra neurons, and induction of
PD-like symptoms (Singer et al., 1987; Betarbet et al.,
2001).
Dopamine synthesis also produces high
amounts of ROS, increasing the likelihood of oxidative
stress in dopamine-producing neurons (Olanow &
Tatton, 1999). Substantia nigra neurons from PD
patients show DNA, protein, and lipid oxidation (Jenner
and Olanow, 1996).   Oxidant stress may directly cause
cell death, or it may modify proteins that then misfold,
aggregate, and interfere with essential cell functions
(figure 2; Giasson et al., 1999).
Familial PD:  This form only constitutes 5% of all PD
cases (Goedbert, 2001), yet the study of involved
genes provides new insights into pathogenesis of all
forms and guides development of new model systems.
At least three mutant genes cause separate forms of
familial PD. Mutations in the α - s y n u c l e i n
(Polymeropolous et al., 1997) and ubiquitin carboxy-
terminal hydrolase L-1 (UCHL-1) genes (Leroy et
al.,1998) cause autosomal-dominant forms of PD.  A
mutation in parkin causes an autosomal-recessive form
of PD (Kitada et al., 1998).  The α-synuclein protein is
abundantly expressed in the substantia nigra where it
regulates dopamine levels (Jenko et al., 1998).  Parkin
and UCHL-1 are enzymes of the ubiquitin-proteosome
pathway that label misfolded proteins for degradation
(Kitada et al., 1998; Leroy et al., 1998).  Four additional
loci may be involved in the disease pathway, indicating
additional contributing genes (Taylor et al., 2002).  This
thesis focuses on α-synuclein.
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Figure 2. Proposed Molecular Mechanisms of Parkinson’s
Disease
Poorly understood environmental factors, and gene mutations
in α-synuclein and ubiquitin ligases cause α-synuclein protein
to misfold and aggregate.  While misfolded α-synuclein may be
toxic, the structural form causing cell death is not well
understood.
Mutations in parkin imply that deficiencies of
proteolytic enzymes are linked to the onset of the
disease (Kitada et al., 1998).  Parkin interacts with a
family of structurally related proteins including α -
synuclein, recognizes misfolded forms of these
proteins, and ubiquitinates them for proteolytic digestion
(figure 3; Kitada et al., 1998).  Mutations in parkin
disrupt its ability to recognize substrate proteins and
label them for degradation (Shimura et al., 2000).
UCHL-1 mutations are more rare in familial PD, but
they also cause the loss of catalytic activity of ubiquitin
transfer to α-synuclein (figure 3; Leroy et al., 1998).
The UCH family of enzymes also cleaves polymers of
ubiquitin into monomeric units (Hershko & Ciechanover,
1998), regenerating pools of free cytosolic ubiquitin.
UCHL-1 mutations may decrease proper ubiquitin
transfer and proteolytic degradation of α-synuclein
(figure 3; Hershko & Ciechanover, 1998). Increased
cytoplasmic concentrations of undigested α-synuclein
may be cytotoxic or facilitate the formation of other toxic
structures (Imai et al., 2000; Shimura et al., 2000).
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Figure 3. Current Model for Interactions Between α -
Synuclein, Parkin, and UCHL-1 in familial PD
Misfolded cytoplasmic proteins are tagged and degraded by the
ubiquitin-proteosome complex. Parkin and UCHL-1 are
ubiquitin ligases that recognize misfolded α-synuclein as a
substrate, and label it for degradation.  Mutations in any one of
these three genes inhibits proper α-synuclein degradation, and
underlies the onset of familial PD (adapted from Cooper, 2000).    
The synuclein family is comprised of three
soluble axon-localized proteins, including α , β , and γ
synucleins (Clayton & George, 1998).  They contain a
high degree of sequence conservation, and may serve
as vesicle-associated proteins in neuronal axons
(Clayton & George, 1998). β and γ-synucleins have not
been implicated in NDDs, and β-synuclein may actually
protect against α-synuclein toxicity (Hashimoto et al.,
2001).  α -Synuclein is a 14 kDa cytosolic protein
abundantly expressed in a variety of neurons and non-
neuronal cells (Duda et al., 1999).   In dopaminergic
neurons of the substantia nigra, α-synuclein is known to
maintain dopamine pools and regulate synaptic
connections (Clayton & George, 1998).  Two point
mutations A53T (Polymeropoulos et al., 1998) and
A30P (Kruger et al., 1998) of the α-synuclein gene are
correlated to separate forms of familial PD.  These
mutant forms of α-synuclein may allow the protein to
misfold and aggregate, and initiate the disease state
(figure 3; Polymeropoulos et al., 1998; Kruger et al.,
1998).   These mutant forms of α-synuclein are found in
insoluble filaments and Lewy bodies from PD patients
(Arima et al., 1998; Spillantini et al., 1998).
α-Synuclein properties in cell culture & test tubes
α-Synuclein misfolds and aggregates in
dopaminergic neurons, a feature that correlates with the
onset of all forms of PD (Goedbert, 2001).   α-Synuclein
aggregation proceeds through several structural
intermediates in test tubes (Conway et al., 2001), but
the toxic intermediates have not been identified
(Conway et al., 2001).  First, monomeric α-synuclein
polymerizes and forms spherical structures that
facilitate its continued reactivity (Ding et al., 2002).
These α-synuclein polymers then rapidly fuse to form
small, insoluble intermediates (Lee & Lee, 2002). These
small intermediates link together to form large fibrils
(Conway et al., 2000).  Mammalian cell culture studies
show that amino acids within these fibrils are targeted
for degradation by the ubiquitin/proteosome complex
(Hershko & Ciechanover, 1998). However these large
fibrils cannot be broken down, and sequester ubiquitin
and parkin during the formation of Lewy bodies
(Trojanowski et al., 1998, Abeliovich et al., 2000).
While Lewy bodies are often found in
conjunction with cell death, some forms of familial PD
do not contain Lewy body pathology (Kitada et al.,
1998), indicating that an intermediate α-synuclein
aggregate may be the toxic form.  However, Lewy
bodies may interfere with protein degradation by
reducing parkin availability.  When parkin levels
decrease, non-digested target proteins may reach toxic
concentrations (Shimura et al., 2000).  For example,
synphilin-1 protein is a substrate for parkin (Chung et
al., 2001).  In cultured cells, synphilin-1 forms insoluble
aggregates with α-synuclein in the absence of parkin
(Chung et al., 2001; Engelender et al., 1999).
However, aggregates do not form under the same
conditions when synphilin is absent (Chung et al.,
2001), showing that high concentrations of synphilin-1
are sufficient for α-synuclein aggregation.
Bacterial expression studies have compared
the aggregation rates of wild type and mutant α -
synuclein forms (Conway et. al. 1998, Giasson et. al.
1999, Conway et. al. 2000, Serpell et. al. 2000).  All
forms polymerize at different rates.  At high
concentrations wild type and mutant (A30P and A53T)
forms polymerize more rapidly than wild type in vitro
(Conway et al., 2000). After polymerization, insoluble α-
synuclein forms fibrils.  A30P α-synuclein forms fibrils
more slowly than WT protein (Serpell et. al.1999,
Conway et al., 2000), while A53T forms fibrils more
quickly (Conway et al., 1998). These studies show that
both mutant forms facilitate polymerization, but do not
necessarily accelerate fibril formation.  Because both
mutant forms accelerate the disease state (Giasson &
Lee, 2001), α-synuclein polymers may be the toxic
structure (Conway et al., 2000), whereas subsequent
structures like fibrils may be non-toxic endpoints.
Moreover, dopamine inhibits α-synuclein fibril formation
in vitro and stabilizes α-synuclein polymers (Conway et.
al., 2001).  Therefore, dopamine may actually stabilize
the toxic α-synuclein polymers, thereby confining
neuronal death to dopaminergic neurons in the
substantia nigra.
Remaining Questions
The mechanisms of α-synuclein misfolding in sporadic
PD are still unknown.  The structure and function of α-
synuclein is central to the study of this disease.  To
date, the toxic form of α -synuclein has not been
identified, and how it participates in the disease state
has not been fully determined.   These questions may
be better addressed when the factors that cause α-
synuclein misfolding are identified.   Likewise, the
interaction of misfolded α-synuclein with members of
the proteolytic pathway is not well understood.  α-
Synuclein aggregates may hinder the activity of the
proteosome by sequestering proteolytic enzymes, or it
may form toxic structures when bound to these
proteins.  Because cell death is largely limited to
dopaminergic neurons, the role of dopamine in PD
pathology needs to be established in vivo.
New Animal Models for PD
To begin to address these questions, several mice
models of PD expressing α -synuclein have been
developed in the past three years.   Overexpression of
human wild-type α-synuclein causes PD-like pathology
and behavior in mice (Masliah et al., 2000).  Severity of
symptoms and cytoplamic aggregates increase with α-
synuclein abundance (Masliah et al. 2001).  While both
wild type and mutant forms of α -synuclein cause
pathology, mutant α-synuclein enhances toxicity when
expressed to similar levels (Van der Putten et al.,
2000).  A recent mouse model of human A53T α-
synuclein expression shows late onset PD-like
behavior, and the cytoplasmic inclusions closely
resemble authentic filamentous fibrils from PD patients
(Giasson et al., 2002). These models show that α-
synuclein over-expression is sufficient for PD in mice,
and the A53T mutant accelerates the disease state
(Giasson et al., 2002).
Like mice and humans, fruit flies have
dopaminergic neurons that coordinate motor
movement.  A fruit fly model of PD expressing human
α-synuclein shows aggregates indicative of human
pathology (Feany & Bender, 2000).  This model system
has already proven useful for exploring possible
regulatory factors.  Chaperone proteins refold cellular
proteins into their correct, functional shape (as
explained on page 2).  Expression of the chaperone
protein Hsp70 in conjunction with human α-synuclein in
flies prevents dopaminergic cell death (Auluck et al.,
2002).  Conversely the inhibition of fly chaperone
proteins accelerates cell death and PD symptoms
(Auluck et al., 2002). If accelerated protein refolding is
sufficient for rescuing cells from PD pathology,
misfolded α-synuclein may be the direct cause of cell
death in PD (as opposed to being a side product of
another toxic process).
Yeast as a model organism for studying human
disease
Saccharomyces cerevis iae  (baker’s yeast) is an
attractive model organism because the ease of working
with a unicellular organism is matched with the
presence of a wide range of evolutionary conserved
eukaryotic genes. Despite over a billion years of
evolutionary separation, yeast contain many of the
same regulatory processes found in humans including
the ubiquitin/proteosome pathway and chaperone
proteins.  This simple, but powerful system has been
used to study basic tenets of the eukaryotic cell cycle
(Elledge et al., 1996), endocytosis (Dulic et al., 1991),
cellular export and import (Guerin et al., 1978), and the
central dogma of genetic flow of information (DNA to
RNA to protein; Paushkin et al., 1997).  Several human
diseases have been investigated in yeast, including the
function of the human ras proto-oncogene in cancer
(Gibbs & Marshal, 1989) and NDD pathology.
Importantly, yeast studies have probed specific protein
interactions and protein misfolding in several NDDs
such as amyotrophic lateral sclerosis (Kunst et al.,
1997), prion diseases (Ma & Lindquist, 1999), and
Huntington’s disease (Krobitsch et al., 2000).
Manipulation of proteosome and chaperone proteins
successfully modulated the misfolding of the huntingtin
protein in yeast (Krobitsch et al., 2000, Muchowski et
al., 2000; Meriin et al., 2002; Muchowski et al., 2002).
The interplay of eukaryotic chaperone proteins,
proteolytic enzymes and misfolded proteins in several
NDDs including PD may be successfully modeled in
this simple and easily manipulated model system.
Specific aims of this thesis
Currently, no yeast model for PD has been established.
With significant initial successes of NDD research in
yeast discussed above we believe that such a model
will facilitate our understanding of how α -synuclein
misfolds.  We can probe the structural characteristics
and compare differences between wild type and mutant
forms of α-synuclein expressed in yeast.  Because
chaperone proteins and the ubiquitin/proteosome
complex have been extensively studied in yeast, their
ability to properly fold different forms of α-synuclein
may be thoroughly investigated.
The specific aims of this thesis were to
develop a yeast α -synuclein expression model,
determine if α-synuclein aggregates in yeast, and
assess if misfolding differences exist between wild type
and mutant forms.  Yeast do not contain a protein
similar to human α-synuclein, so we put wild type and
three mutant forms of human α-synuclein (A53T, A30P,
A53T-A30P) into yeast.  All four forms of α-synuclein
protein were made in yeast, and all forms appear to be
structurally modified.  All forms of α-synuclein have
been purified and evidence from multiple assays
supports that α-synuclein may be misfolding in yeast.
Ongoing and future experiments to understand protein
shape and solubility will compare the molecular
characteristics and behavior of wild type and mutant α-
synuclein.
Results
Wild type and mutant α -synuclein yeast vectors
created and amplified in E. coli
Our first goal was to subclone α-synuclein into a vector
(figure 5a; pYES2.1/V5-His-TOPO; Invitrogen) chosen
for the following features.  First, the vector contains the
pUC and 2µ origins for high copy replication and long-
term storage in bacteria and yeast.  Secondly, the
vector contains an ampicillin-resistance gene and a
URA3 gene.  These genes allow selection of vector-
containing bacteria and yeast in the presence of
ampicillin (a drug that kills bacteria) and in media
lacking uracil (a yeast nutrient required for making
RNA), respectively.  Thirdly, it contains the galactose-
sensitive G A L 1  promoter next to the subcloned
transgene that allows the experimenter to induce
expression of the transgene at will by growing yeast in
galactose.  Lastly, this vector adds two small epitopes
to the protein expressed from the transgene.  The
added V5 epitope (14 amino acids long) allows
detection of protein via the use of an anti-V5 antibody.
The second added poly-histidine epitope (six amino
acids long) allows one-step purification of protein, using
nickel column chromatography.
PCR-amplified wild type and A53T α -
synuclein were subcloned into this vector, which were
respectively named pWTα -syn and pA53Tα -syn.
These vectors were transformed into chemically
competent E. coli, and cells that contained the vector
were selected for growth in ampicillin-containing media
(figure 5b).   The vectors were purified from bacteria
and screened for the presence of the transgene through
restriction digestion (data not shown), forward
orientation of transgene through PCR with respect to
the Gal1 promoter (figure 5c), and sequence
confirmation of transgene through DNA sequencing
(data not shown).
WT and A53T α -synuclein transformed and
expressed in yeast
Our next goal was to transform purified pWTα-syn and
pA53Tα-syn into a haploid strain of Saccharomyces
cerevisiae (MATα ade-2-1-1 his3-Δ200 leu2-3, 112
ura3-52) lacking a chromosomal copy of URA3 (a gene
required for the synthesis of uracil).  Cells containing
pWTα-syn and pA53Tα-syn were selected for growth in
media lacking uracil (figure 5d), and screened for the
presence of α-synuclein using whole cell colony PCR
(figure 5e).
Next, we induced the expression of α -
synuclein protein in these yeast and determined optimal
yield conditions.  Yeast containing pWTα-syn and
pA53Tα-syn were grown in uracil-lacking media with
either galactose or glucose as the sugar source.
Galactose binds to the GAL1 promoter and induces α-
synuclein expression, whereas glucose inhibits this
process.  Cells were drawn from the culture at 0 h, 3 h,
6 h, 12 h, 24 h, 36 h, and 48 h after induction.  The
expression of α-synuclein was determined by Western
blot analysis, using the anti-V5 antibody.  The predicted
size of α-synuclein is 19 kDa (including the 5 kDa
epitope tags).  As expected, yeast that grew in glucose
media did not express α-synuclein over this time course
(figure 6).  But, when induced with galactose, a 28 kDa
band appeared from both pWTα-syn and pA53Tα-syn -
containing cells (figure 6).  Protein was maximally
expressed in both types of cells by 24 h.  We assigned
the 28 kDa band to be α-synuclein, presumably post-
translationally modified by a mechanism yet to be
determined. To confirm that these bands were truly α-
synuclein, a Western blot containing pWTα-syn yeast
lysate was probed with an anti-α-synuclein monoclonal
antibody (figure 6c).  The single band closely matched
the migration of α -synuclein as determined from
previous anti-V5 antibody probed blots (6a & b).
Two additional mutants (A30P and A30P/A53T)
created and expressed in yeast
We then created the A30P α -synuclein
mutant in order to compare protein folding
characteristics between A30P and A53T, the two known
mutations of α-synuclein found in PD patients.  We also
combined the two point mutations in the same
transgene to assess if the double mutant would
accelerate protein misfolding and be more toxic.  To
create these two mutations, a site-directed base pair
substitution was made at codon 30 of α-synuclein onto
the parent pWTα-syn and pA53Tα-syn vectors (as
described in methods). The resulting vectors were
designated pA30Pα -syn and pA30P/A53Tα -syn,
respectively.  The mutation was confirmed by DNA
sequencing (data not shown). These vectors were then
transformed into yeast, and protein expression was
induced and probed by Western analysis, as done
before.  Just as before, a 28 kDa band appeared in
cells induced with galactose, but not glucose (figure 7).
Once again, maximal protein expression occurred by 24
h, but interestingly a minor, higher-running band at ~34
kDa was detected in A30P-expressing cells.  Also, a
weak, lower band at ~16 kDa was seen in both mutant
forms, presumably degradation products.
To demonstrate that α-synuclein expression
required the α-synuclein transgene, we also grew yeast
cells that simply contained the parent pYES2 vector
(without α -synuclein transgene) with glucose or
galactose.  As shown in figure 8a, these cells do not
express α-synuclein under either condition, while cells
that contain α -synuclein-specific pYES2 vectors
express the protein only in the presence of galactose.
To demonstrate that glucose treated (non-induced)
cells contained the same amount of total cellular protein
as galactose treated (induced) cells, we probed a
duplicate blot with an antibody against RSP5, an
abundant house-keeping protein required for yeast
survival (Hein et al., 1995).  As expected, RSP5 is
expressed to similar levels in all cells, irrespective of α-
synuclein expression or sugar source (figure 8b).  In
these blots protein samples were prepared from the
same number of yeast cells, which was confirmed by
the overall staining profile of the RSP5 antibody in all
lanes of figure 8b (because the RSP5 antibody titer is
high, this antibody was used in crude serum form and
resulted in the high background staining; Linda Hicke,
personal communicat ion).  Independently,
Figure 5. Transformation of Wild Type and A53T α-Synuclein into Bacteria and Yeast
A: pYES2.1/V5-His-TOPO vector map.  The vector contains the pUC and 2( origins for replication in bacteria and yeast; ampicillin
resistance and URA3 genes to allow selective growth of vector-containing bacteria and yeast; the GAL1 promoter to allow galactose
induced expression of the transgene; and the V5 and 6x-His sequences that provide an antigen for immunostaining, and a poly-histidine tag
for nickel column protein purification.  B:  PCR-amplified wild type and A53T (-synuclein, subcloned into the pYES2.1/V5-His-TOPO vector
were transformed into E. coli.  Only cells containing the expression vector should survive.  Cells were plated on LB-ampicillin selective
media.  C: PCR amplification of WT and A53T (-synuclein from E. coli.  The primer pair amplified a 550 bp (*) product if (-synuclein were
subcloned into the expression vector in the forward orientation.  D:  WT and A53T (-synuclein transformed into S. cerevisiae.  Cells were
plated on uracil-lacking media, and only cells containing the expression vector should survive.  E:  Yeast colony PCR amplification of WT
and A53T (-synuclein with the same primer pair used in B.  The primer pair amplified a 550bp (*) product if (-synuclein was in the forward
orientation.  For B & D, 1% agarose gels resolved DNA.  The left lane is a size standard.
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Figure 6.  Western Blot Analysis of Timecourse Expression of Wild Type and A53T α-Synuclein
Induced Expression of (A) wild type and (B) A53T α-synuclein in yeast grown in uracil-lacking media containing galactose (right-hand side
of blot) and glucose (left-hand side of blot).  Yeast cells were removed from culture at successive intervals, and equivalent cell lysate
concentrations were loaded into each well.  Blots were probed with anti-V5 antibody that specifically bound to the V5 epitope tag of (-
synuclein. For A & B, (-synuclein size was compared to a protein ladder (M). (-Synuclein migrated to approximately 28 kDa.  Red arrow
indicates size of fragment predicted by amino acid sequence (19kDa: 14 kDa (-synuclein + 5 kDa tag).  C: Wild type cell lysate probed with
anti- (-synuclein antibody.
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Figure 7. Western Blot Analysis of Timecourse Expression of A30P and A30P/A53T α-Synuclein
Induced Expression of (A) A30P and (B) A30P/A53T α-synuclein in yeast grown in uracil-lacking media containing galactose (right-hand
side of blot) and glucose (left-hand side of blot). Yeast cells were removed from culture at 12 h intervals, and equivalent cell lysate
concentrations were loaded into each well.  Blots were probed with anti-V5 antibody that specifically bound to the V5 epitope tag of α-
synuclein. For A & B, α-synuclein size was compared to a protein ladder (M). α-Synuclein migrated to approximately 28 kDa.  Red arrow
indicates size of fragment predicted by amino acid sequence (19kDa: 14 kDa (-synuclein + 5 kDa tag).  Higher (*, ~34 kDa) and lower (**,
~16 kDa) migrating bands.
equivalent protein loading was confirmed in time course
experiments previously shown in figures 6 & 7, and in
the experiment shown in figure 8 by Coomassie
staining (data not shown).
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Figure 8. Expression of (-Synuclein is Specific for Yeast
Carrying Transgene and Does not Affect Overall Protein
Expression
Yeast transformed with control vector, wild type and mutant
forms of (-synuclein were grown in uracil-lacking media
containing galactose (+) or glucose (-) for 24 h. Duplicate
Western blots of whole cell lysates, probed with (A) Anti-V5 Ab
& (B) Anti-RSP5 Ab.  Lanes: (1-2) pYES2;  (3-4) WT; ( 5-6)
A30P; (7-8) A53T; (9-10) A53T/A30P.  RSP5 is a 200kDa
protein that is unaffected by (-synuclein expression.
α-Synuclein does not drastically affect cell growth,
but may affect adenine metabolism
Previous studies have shown that (-synuclein is toxic to
nerve cells (Masliah et al., 2001a), so we asked if (-
synuclein affected yeast cell growth.  We compared a
48 h growth curve of yeast cells that expressed (-
synuclein (wild type or mutant), cells that contained
parent pYES2 vector, and cells that expressed the non-
toxic protein β-galactosidase.   Cells were grown in
either glucose or galactose.  Cell density of the cultures
was determined by counting cells with a
hemocytometer under a microscope at 0 h, 3 h, 6 h, 9
h, 12 h, 15 h, 24 h, 30 h, 36 h, and 48 h.  First, cells
grown in galactose demonstrated a delayed log phase
of growth with respect to cells grown in glucose media,
presumably due to metabolic transition time needed by
yeast cells when exposed to an alternate sugar source
(figure 9a; compare dashed lines to solid lines).  More
interestingly, little or no difference was observed
between cell growth patterns under induced conditions,
irrespective of α-synuclein expression (figure 9a).
Therefore, α-synuclein appears not to drastically affect
cell growth.
However, yeast culture coloration differences
were observed between expressed forms of α -
synuclein.  When exogenous adenine levels are limited,
Figure 9. Expression of α-synuclein does not affect yeast growth, but may affect metabolism.
α-synuclein were grown in uracil-lacking media, containing galactose(--->  or glucose). 5 mL of cells were periodically removed from
culture, and counted using a hemocytometer chamber under a microscope. Growth was compared to cells transformed with pYES and
LacZ under the same conditions. B: Changes in culture media color were assessed over a 48 h time course at 30ϒC in uracil-lacking media
containing galactose. Photographs were taken with a digital camera.
yeast initiate adenine biosynthesis.  The host yeast
strain used in this study lacks a chromosomal copy of
the ade2 gene necessary for adenine synthesis.
Instead of forming adenine, these yeast only synthesize
t h e  i n t e r m e d i a t e  m e t a b o l i t e
phosphoribosylaminoimidazole (AIR) that is transported
to the yeast vacuole for degradation (Chaudhuri et al.,
1996).  In the vacuole, AIR gets structurally modified
and turns red (Chaudhuri et al., 1996).  Here we show
that the form of expressed α -synuclein affected the
shade of media coloration over a 48 h time course.
Media containing wild type and A53T expressing α-
synuclein turned a dark shade of red over 48 h (figure
9b). Media containing A30P-expressing cells were
lighter than wild type, and A30P/A53T-expressing cells
became least red of all forms (figure 9b).  These
differences may indicate differences between wild type
and mutant yeast metabolism or trafficking.
α-Synuclein purified from yeast under denaturing
and native conditions
We purified α -synuclein from yeast to
conduct future in vitro biochemical experiments.  All
forms of α-synuclein have a propensity to aggregate in
human neurons, and α-synuclein expressed in bacterial
cells require chemical denaturants for purification
(Serpell et. al. 2000, Conway et. al. 1998, Giasson et.
al. 1999, Conway et. al. 2000b).  Therefore, we first
purified wild type α -synuclein from yeast under
denaturing conditions.  Some protein remained
insoluble after cell lysis and centrifugation at 5000 x g
(figure 10a, lanes 1&2), whereas the majority of the
protein remained in the soluble portion of the lysate
(figure 10a, lane 3).   No significant amount of protein
was washed from the column prior to elution (figure
10a, lanes 4-9).  α-Synuclein protein was eluted from
the nickel column during the first three 1 mL elution
fractions (figure 10b, lanes 1-3).
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Figure 10 : Purification of Wild Type α-Synuclein.
A: α-synuclein remaining in the cell pellet after cell lysis and
centrifugation (1-2), soluble α-synuclein in supernatant prior to
purification (3), protein washed from the purification column
prior to elution (4-9).  B: α-synuclein eluted from column (1-4),
protein marker (M).
We then repeated the same purification procedure for
the mutant forms under denaturing conditions.  Total
cell lysates for the wild type and each mutant were
probed for the presence of α-synuclein (figure 11a, lane
1).  A majority of α-synuclein remained in the insoluble
fraction of the cell lysate (figure 11a, lane 2).  We
observed no significant differences in the amount of
insoluble α-synuclein between wild type and mutant
forms (compare figure 11a, lane 2).  Similar amounts of
α-synuclein protein were eluted from the purification
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Figure 11. α-Synuclein protein purification under native and denaturing conditions
Western analysis of α-synuclein purified from yeast under denaturing conditions (A):  Total cell lysate (lane 1); insoluble fraction of cell
lysate (lane 2); purified α-synuclein from soluble fraction of cell lysate (lane 3);  10-fold concentration of purified α-synuclein (lane 4).
Protein purified under native conditions (B): Total cell lysate (lane 1); insoluble fraction of the cell lysate (lane 5); purified α-synuclein from
soluble fraction of cell lysate (lane 6);  10-fold concentration of purified α-synuclein (lane 7).  All blots were probed with anti-V5 Ab.
column for each wild type and mutant form (compare
figure 11a, lane3), and eluted protein was concentrated
ten fold (figure 11a, lane 4).  Notably, in addition to the
prominent band at ~28 kDa, Western analysis showed
an additional α-synuclein band running to ~34 kDa for
all forms with highest intensity occurring in
concentrated A30P and A30P/A53T protein.
Next, we asked if wild type and the three
mutant α-synuclein forms could be purified under native
conditions.  We hypothesized that mutant proteins
would be more difficult to purify under these conditions
due to their greater tendencies to aggregate (Conway
et al., 1998, Giasson et al. 1999) and fall out of solution.
α-Synuclein abundance was measured in total cell
lysates (Figure 11b, lane 1), and in the insoluble lysate
fraction after 5000 x g centrifugation (Figure 11b, lane
2).  The amount of α-synuclein remaining in the cell
pellet was consistent between wild type and mutant
forms under native and denaturing conditions (Compare
figure 11a and 11b).  All α -synuclein forms were
subsequently purified from the soluble cell fraction of
the cell lysate (figure 11b, lane 3) using nickel column
chromatography, and were concentrated (figure 11b,
lane 4).  An additional band ran to ~34 kDa in the
concentrated A30P sample, similar to the Western
profile of this mutant form concentrated under
denaturing conditions (compare figure 11a and 11b).
We also bead-beat cell lysates before centrifugation to
further ensure lysis had indeed occurred, and this step
had no impact on protein solubility (data not shown).
Cell lysis with bead-beating was sufficient to recover β-
galactosidase in the soluble fraction at 5000 x g (figure
11).  We determined the amount of concentrated
protein purified under native and denaturing conditions
(table 1).  More wild type protein was quantified than all
three mutant forms, with purified A30P/A53T showing
lowest yield.
Table 1. Purified α-synuclein protein concentrations
α-Synuclein remains in yeast after loss of induction
We asked if α-synuclein stability in yeast required a
continuous supply of newly synthesized protein, and
how quickly would the protein be degraded in the
absence of induction.  We first grew yeast containing α-
synuclein to saturation (figure 12, - lane), and then
induced α-synuclein expression in galactose for 24 h.
Pelleted cells were transferred back to glucose, and the
presence of α-synuclein was periodically determined
over the next 60 h.  Western analysis showed that no
wild type α-synuclein remained in the cell media 12h
after loss of induction (figure 12, 12 -60 h).  All mutant
forms of α-synuclein remained in cell media for 60 h
after loss of induction.  In addition to a 28 kDa band, up
to two more bands running to ~34 kDa were most
prominent in A30P/A53T lysates. Lower running α-
synuclein bands (~6-16 kDa) presumably were partial
α-synuclein degradation products.
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Figure 12. α–synuclein Stability Assessment After Loss of Gene Induction.
Cells expressing all forms of α-synuclein were grown in glucose-containing media for 24 h and cell lysates were probed for (-synuclein
expression (-).  Cells were transferred to galactose-containing media for an additional 24 h and cell lysates were probed for (-synuclein
expression (0).  Finally cells were returned to glucose-containing media (-).  200 (L cell samples were removed from glucose containing
media at 12 h intervals and probed for (-synuclein expression (12-60). Molecular marker (M).
α-Synuclein Concentration
(native)
Concentration
(denatured)
Wild type 153 µg/mL 54 µg/mL
A30P 55 µg/mL 41 µg/mL
A53T 53 µg/mL 36 µg/mL
A30P/A53T 13 µg/mL 24 µg/mL
Wild type A30P
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Figure 13. High Speed Centrifugation Pellets Wild Type and
A30P (-Synuclein.
Cell lysates containing (-synuclein (1) were centrifuged at
11,000 x g or 110,600 x g for 30 min; soluble (-synuclein (2 & 4,
respectively) was separated from the pelleted fraction (3 & 5,
respectively). Purified (-synuclein (6) was centrifuged at 11,000
x g or 110,600 x g; the soluble fractions (7 & 9, respectively)
and insoluble fraction (8 & 10, respectively) were probed for (-
synuclein.
(-Synuclein pellets at low centrifugal force
Previous in vitro studies show that mutant forms of α-
synuclein tend to aggregate more rapidly than wild type
α-synuclein (Conway et al., 2000a ).  We probed for
protein solubility differences among wild type and A30P
α-synuclein by a preliminary differential centrifugation
assay.  Cell lysates and purified protein were
centrifuged at two speeds.  For cell lysates, both wild
type and mutant α-synuclein were totally separated into
the pelleted fraction at low force (11, 000 x g; figure 13,
compare lanes 2 & 3).  Likewise, at higher force
(110,600 x g) both forms of α-synuclein also pelleted
(figure 13, compare lanes 4 & 5).  Surprisingly, α -
synuclein purified and concentrated one week earlier
was not detected by Western analysis.  While this part
of the experiment failed, it suggests that purified α-
synuclein only remains soluble for a short period of
time.  To capture differences in solubility, we may need
to centrifuge below 11,000 x g and use freshly purified
protein.
Discussion
A major challenge in PD research has been finding
effective ways to reverse or prevent protein aggregation
and cell death associated with this disease.
Development of diverse model systems will accelerate
such discoveries.  Baker’s yeast has served well to
model aspects of other NDDs (Kunst et al., 1997, Ma &
Lindquist, 1999, Krobitsch et al., 2000).  We created a
yeast system for α-synuclein expression and evaluated
its ability to model protein misfolding associated with
PD. This study has four notable findings worth
discussing.  First, we show that all forms of
recombinant human α-synuclein expressed in yeast
appear larger in size than predicted on protein gels.
Secondly, none of these α-synuclein forms adversely
affects yeast growth, but mutant forms may have
altered metabolism.  Thirdly, while all forms were
purified from yeast under native and denaturing
conditions, mutant forms more often show multiple
sizes on protein gels more prominently than wild type
protein.  Lastly, preliminary results suggest that mutant
α-synuclein is more slowly degraded in yeast than wild
type protein.  With this model we can begin to analyze
how α-synuclein interacts with partners proteins, and
genetically screen factors that may inhibit α-synuclein
misfolding.
Altered migration of α-synuclein suggests post-
translational modification
Our first major finding is that α-synuclein from yeast
lysates migrates to approximately 28kDa in denaturing
protein gels in contrast to the predicted mass of 19 kDa
(14 kDa protein + 5 kDa epitope tags).  We also often,
but not always, find faint bands between 30-34 kDa
from cell lysates.  Interestingly, we did see α-synuclein
run to the predicted 19 kDa (figure 12; A30P/A53T, 0
h), but only once.  Published sizes of human and
recombinant α-synuclein have been reported in several
models (E. coli, mice, and rats) as summarized in Table
2.  In both human patients and in E. coli the expected
14 kDa size was only seen in three reports (Conway et
al., 2000 b; Uversky et al., 2001; Hasegawa et al.,
2002).  In others α -synuclein models size varied
between 16-19 kDa without any obvious added protein
epitopes contributing to their reported sizes (Spillantini
et al., 1998; Okochi at al., 2000; Shimura et al., 2001;
Ellis et al., 2001; Kahle et al., 2000; Sharon et al., 2001;
Masliah et al., 2001; Bianco et al., 2002; Biere et al.,
2000).  Our observed 28 kDa α-synuclein band is
consistent with these reports of aberrant synuclein
migration.  However, no clear explanations have been
provided for the majority of increased sizes in previous
studies with the following exceptions: Okochi et al. 2000
report a band at 25 kDa in addition to 19 kDa due to
serine phosphorylation (addition of phosphate groups);
Shimura et al. 2001 report α-synuclein running to 22
kDa in addition to 16 kDa caused by glycosylation
(addition of sugars); and Sharon et al. 2001 show α-
synuclein running to 36 kDa due to lipidation (addition
of lipids).  While we do not know why synuclein
migrates to 28 kDa in our study, it may be due to one or
more of these three forms of post-translational
modifications.  Currently, we are conducting
experiments to examine N-linked and O-linked
glycosidases and phosphatases (enzymes that cleave
sugars and phosphates, respectively) on purified and
cell lysate forms of α-synuclein.
Additonally, studies summarized in Table 2 show high
running synuclein dimers and other aggregates
(Uversky et al., 2001; Sharon et al., 2001; Masliah et
al., 2001).  These variations were attributed to
temperature, time, and pH dependant conditions
(Giasson et al., 1999).  We have not observed any α-
synuclein bands running higher than 34 kDa on
denaturing gels (to be a dimer α-synuclein would have
to run to 38 kDa).  Either α -synuclein may not be
aggregating to dimers and higher order structures to
significant amounts in yeast, or aggregates do form but
get separated during denaturation steps before loading
proteins on gels for
electrophoresis analysis.  Future experiments with
purified protein will examine temperature, time, or pH
dependant aggregation.
Previous studies have not reported any
significant differences between wild type and mutant α-
synuclein migration on protein gels.  Similarly we see
wild type and mutant forms
migrating to the same extent on protein gels, except
that the higher running bands (~30-34 kDa) are more
intense for mutant protein (discussed below).
Subtle metabolic differences may indicate α-synuclein
toxicity otherwise not apparent by yeast survivability
Our next result indicates that yeast growth
rates are relatively unaffected by α - synuc le in
expression.  The yeast genome does not have an α-
synuclein gene, and the presence of this foreign protein
does not appear to be lethal.  Overexpression of α-
synuclein in other model organisms (fruit flies and mice)
that do naturally make this protein (they have an α-
synuclein gene) show that α-synuclein misfolds and
forms insoluble fibrils in dopamine-producing neurons,
causing cell death (Masliah et al., 2000; Van der Putten
et al., 2000; Giasson et al., 2002; Feany & Bender,
2000).  Moreover fruit flies and mice that overexpress
α -synuclein closely resemble the pathology and
symptoms of human PD (Feany and Bender 2000,
Giasson et al 2002).  Fruit flies and mice share many
cellular processes with human cells that allow PD
pathology and symptoms to be closely recapitulated.
However, yeast do not age, degenerate or have a
programmed cell death pathway like human cells and
may not die as easily from toxic forms of α-synuclein.
Other endpoints to measuring cellular toxicity need to
be further investigated.  We are currently confirming
effects of α-synuclein on yeast growth by spotting
serially diluted yeast on glucose and galactose yeast
culture plates.
Serendipitously, we noted differences in
media coloration (associated with adenine metabolism)
among yeast expressing wild type and mutant forms of
α-synuclein, when examined over a 48 h time course.
One possibility is that A30P and A30P/A53T α -
synuclein is inhibiting the transport of the adenine
precursor metabolite AIR to the yeast vacuole.  If so,
how can yeast growth remain unaffected if adenine
synthesis is slowed?  In our experiments yeast were
grown in media that contains all amino and nucleic
acids (except uracil).  Yeast metabolism may be
affected by α-synuclein, but growth in this rich medium
may mask any potential toxicity.  If adenine
biosynthesis pathways are differentially affected in
yeast expressing mutant α-synuclein (this was easy to
examine), it stands to reason that other process may be
affected. Alternatively, these differences may be due to
slowed metabolic processes in these cells that cannot
be captured in growth rates in enriched media.  Instead,
yeast can be grown in media deficient in essential yeast
nutrients to determine if α-synuclein interferes with
yeast metabolism.
Several yeast model systems have been
successfully used to study protein misfolding
characteristics of NDDs without affecting yeast
survivability.  Yeast models of Huntington’s disease
show that transgenic expression of wild type or disease
causing forms of huntingtin aggregate, but are not toxic
to yeast (Krobitsch & Lindquist, 1997).  Cytoplasmic
aggregation of the human prion protein in yeast
recapitulates many protein structure aspects of human
prion diseases, but does not appear to be lethal (Ma &
Lindquist, 1999).  Yeast expression of a mutant form of
human superoxide dismutase that causes ALS has
been used to identify some of its partner proteins, but
does not affect yeast growth on rich media (Kunst et al.,
1997).  To determine if factors causing ALS in humans
are toxic to yeast, growth analyses were conducted
under stressful conditions.  Yeast growth rates were
inhibited when grown on medium lacking amino and
nucleic acids, showing that genetically modified yeast
were unable to biosynthetically produce necessary
nutrients (Nishida et al., 1994).  Affected yeast cultured
in a 100% oxygen atmosphere did not grow, indicating
that yeast were unable to detoxify high concentrations
of respiration byproducts (ROS; Nishida et al., 1994).
These assays may be used in our research to
comparatively examine α-synuclein toxicity in yeast.
α -Synuclein sediments in vitro and may form
several monomeric structures
Three lines of evidence support the insoluble
nature of α-synuclein protein in yeast, difficulty in
maximizing purification yield, and preserving long-term
solubility.  First, a significant portion of α-synuclein
sediments from cell lysates at 5000 x g during the first
step of protein purification.  This pelleting is universally
found when purified wild type or mutant protein under
denaturing or native lysis conditions.  Two possibilities
may explain this phenomenon.  α-Synuclein may form
insoluble structures in yeast that are separated into the
cell pellet fraction at low centrifugation.  In initial support
of this, α-synuclein sedimented after treatment under
stringent denaturing conditions (6 M guanidinium
buffer). Alternatively, α-synuclein may not be released
from intact cell as a result of incomplete cell lysis.  To
test this latter possibility we conducted two
experiments.  In addition to lysing cells in the presence
of lyticase, we bead-beat cells for 3 min at high speed,
and centrifuged the lysate at 11,000 x g.  At this slightly
higher speed all protein was fractioned into the cell
pellet.  We also assessed the fractionation of
recombinant β-galactosidase, a known soluble protein
under the same conditions of centrifugation.  This
alternative was tested by purification of the soluble,
cytoplasmic protein β-galactosidase from yeast.  All β-
galactosidase remained soluble under denaturing and
native conditions, demonstrating that cells were lysed
well enough to fully extract soluble protein.  Secondly,
lower yields of purified mutant α-synuclein were
recovered than wild type protein, suggesting that
mutant forms may be less soluble.  Thirdly, after
purifying soluble α -synuclein and confirming its
presence on Western blots, we were unable to visualize
it on a Western blot one week later during a subsequent
experiment (compare presence of protein in figure 11 to
absence of protein in figure 13).
As previously mentioned we often see up to
three different structural forms of α-synuclein (between
28-34 kDa on protein gels; figure 11, lane 1).  This
finding is striking because such close running multiple
bands on protein gels have not been reported for α-
synuclein from E. coli, mice, or humans (Table 2).
Higher running bands (between 30-34 kDa) are most
consistently seen with mutant forms and/or when
purified protein is concentrated.  Interestingly, mutant
α-synuclein tends to aggregate more than wild type
protein as seen in other animal models (Giasson et al.,
2002; Feany & Bender, 2000).  Also, when synuclein is
concentrated, it tends to aggregate, as seen in E. coli
studies (Conway et al., 2000 b; Uversky et al., 2001).
We speculate that the higher running bands we observe
in yeast are associated with aggregation.
Because these bands run too low to be dimeric
structures, we hypothesize that these bands indicate
structurally distinct and stable monomers.  Several
studies have identified structural intermediates that may
be part of the unfolding pathway for α-synuclein
aggregation (figure 14a, reviewed in Goldburg &
Lansbury, 2000).  But less is known about the native
state of α-synuclein, the types of stable monomeric
structures it may adopt, and the role of potential post-
translational in acquiring these states (figure 14b).
Future experiments with native gels may better resolve
these monomeric structures and allow us to visualize α-
synuclein dimers or polymers that may be forming in
yeast.
Mutant α-synuclein may form stable aggregates in
vivo
Wild type α-synuclein protein is undetectable
within 12 h of loss of gene induction, but mutant forms
remain in yeast even 60 hours after α -synuclein
expression is suppressed.  These results suggest that
wild type protein is more easily degraded whereas the
mutants are more resistant.  A continuous supply of
newly synthesized protein does not seem necessary for
the increased stability of mutant α-synuclein, coinciding
with the SDS-resistant bands resolved on protein gels.
This indicates that the mutant forms of α-synuclein may
be forming aggregates that recapitulate properties of
PD-causing structures in human neurons and in model
organisms (Okochi et al., 2000; Van der Putten et al.,
2000; Giasson et al., 2002; Feany & Bender, 2000).
The loss of induction assay was only conducted once,
and must be repeated to confirm this finding.  These
data also show inconsistent tapering of α-synuclein
abundance during loss of induction, probably due to
improper protein loading although cell lysates were
prepared from the same number of cells.  To control for
loading in future experiments, duplicate Western blots
would be probed with an antibody against a
continuously expressed house-keeping protein, and
loss of induction will be compared to soluble β -
galactosidase.  Lastly, this result will be refined by
conducting a pulse-chase experiment that will measure
the lifetime of newly synthesized α-synuclein in yeast
using radioactive-labeled protein.
Future Investigation
In addition to several experiments suggested
throughout this discussion, protease digestion
experiments are being developed to characterize
differences between wild type and mutant α-synuclein
tertiary structures.  α-Synuclein misfolding has been
correlated with mitochondria damage in PD patients,
and these effects can easily be studied in this yeast
system.  Perhaps we can get better yield if we express
α-synuclein to lower levels.  A copper-binding promoter
can more finely control α-synuclein induction, and α-
synuclein concentration dependant aggregation and
mitochondria damage assays may then be developed.
Yeast contain highly conserved eukaryotic chaperone
and ubiquitin/proteosome proteins that regulate protein
misfolding and degradation. Co-immunoprecipitation
assays may show if α-synuclein complexes with these
proteins or is ubiquitinated. Immunofluorescence will
show α-synuclein localization in fixed cells, and green
fluorescent protein (GFP)-tagged α-synuclein will be
used to visualize α-synuclein in living yeast.  The
effects of overexpressed or gene knock-outs of
ubiquitin/proteosome enzymes and chaperone proteins
in this yeast system will be evaluated by identifying
changes in α -synuclein localization with the GFP
expression system.
Conclusion
To our best knowledge, this is the first study to show
wild type and mutant forms of α-synuclein expressed in
yeast.  Initial evaluation of this expression system
indicates that α-synuclein may aggregate in yeast and
in test tubes. Preliminary results indicate that mutant α-
synuclein forms affect yeast metabolism, are more
stable in yeast compared to wild type, and have a
greater tendency to aggregate in vitro.  This model
does recapitulate many properties reminiscent of α-
synuclein behavior in PD patients and will be a useful
model to identify factors that may inhibit or correct α-
synuclein misfolding.
Experimental Procedures
Transformation into E. coli
Gene Amplification: Wild type and A53T α-synuclein cDNA-
containing vectors were a gift from Chris Ross (Johns Hopkins
University).  These vectors were extracted from E. coli using a
standard Qiagen miniprep protocol. Wild type and A53T α-
synuclein cDNA was amplified using polymerase chain reaction
(PCR).  The following α-synuclein-specific primer sequences
were synthesized to allow for subsequent subcloning into the
pYES2.1 TOPO TA vector.
F o r w a r d  P r i m e r  1  ( F P 1 ) :
5'AAAAAAGAGCTCATGGATGTATTCATGAAAGGA3'
R e v e r s e  P r i m e r  1  ( R P 1 ) :
5'GCCTTCAGGTTCGTAGTCTTGATACCCTTC3'
The forward primer contained a 5' overhang with a unique Sac I
restriction site.  cDNA was amplified with the following
thermocycle profile: 30 cycles at 95o C for 30s, 55o C for 30 s,
72o C for 30 s; 72o C 5 min.  Confirmation of PCR product with
an expected size of 442 bp was analyzed by electrophoresis on
a 1% agarose gel.
Sub-cloning and transformation of α-synuclein into E. coli: The
PCR product from the preceding section was subcloned into the
pYES2.1/V5-His-TOPO expression plasmid as described by the
Invitrogen pYES2.1 TOPO TA cloning kit (K4150-01).  The
plasmid was then transformed into chemically competent E. coli
(F'{lacIqTn10(TetR)}mcrAΔ(mrrhsdRMSmcrBCΦ80lacZΔM15Δla
cX74recA1deoRaraD139Δ(araleu)7697galUgalKrpsL(StrR)endA
1nupG). The cells were grown on LB-ampicillin plates to select
for colonies containing the vector.  Twenty colonies from each
plate culture were randomly selected and grown in liquid LB-
ampicillin media.  Vector DNA from each of these cultures was
extracted by Qiagen miniprep.
Analysis of gene orientation
Three tests were conducted to confirm the presence of vector
DNA, the forward orientation of α-synuclein cDNA with respect
to the Gal1 promoter, and the exact sequence of α-synuclein
cDNA in the vector.  First, a restriction digest reaction was
completed on all twenty colonies.  Purified vector from the
twenty screened colonies was incubated with Sac I and Xba I
restriction enzymes for 24 hours.  The Sac I restriction site was
previously engineered into the forward primer used to PCR-
amplify α-synuclein cDNA. The Xba I restriction site was
located on the vector 96 bp downstream from the α-synuclein
cDNA insert.  The results of the digest were analyzed by gel
electrophoresis.  An expected size of 547 bp band indicated the
presence of α-synuclein in the vector in the forward orientation.
Secondly, α-synuclein cDNA was amplified using the same
PCR cycle profile from the gene amplification section. A forward
primer (GAL1 FP: 5'AATATACCTCTATACTTTAACGTC3')
designed by Invitrogen to bind to the vector at the galactose
promoter region upstream from the gene insert was used in this
reaction.  The PCR product with an expected size of 547 bp
was analyzed by gel electrophoresis using a 1% gel. Thirdly,
purified vector solutions containing wild type α-synuclein cDNA
and A53T α-synuclein cDNA were sequenced at the University
of Chicago sequencing facility, using the GAL1 FP.  Bacterial
cells containing the sequenced vector with the gene in the
correct orientation were preserved at -80O C.
Site-Directed Mutagenesis
Methylation: A30P mutant α-synuclein and A30P/A53T α-
synuclein cDNA were mutagenized from wild type and A53T α-
synuclein, respectively.  The protocol for this method was
published in Gene Tailor Site-Directed Mutagenesis System:
12397-014.  1.6 µL methylation buffer, 1.6µL 10x SAM buffer, 1
µL DNA methylase, and 10.8 µL were added to 1µL purified
plasmid DNA containing α-synuclein.  The reactions were
incubated at 37oC for one hour.
Mutagenesis reaction: A PCR reaction was used to amplify
vector DNA with a new point mutation.  Primers were designed
to make the specific A30P mutation, which is underlined (FP: 5'AACAAGGTGTGGCAGAAGCACCAGGAAAGAGAA3'
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Figure 4: Proposed Schematic for α-Synuclein Expression and Characterization in Yeast.  The α-synuclein cDNA was sublconed into
a galactose inducible expression vector, amplified in bacteria, purified, and transformed into yeast.  Expression of α-synuclein was induced
in the presence of galactose.  Growth and metabolism studies were determined in yeast expressing wild type and mutant forms of α-
synuclein.  Whole cells, lysates, and purified protein were used to conduct several tests including loss of induction and differential
centrifugation assays.
RP: 5'TGCTTCTGCCACACCCTGTTTGGTTTTCTC3').
PCR cycle: 94o C for 1 min; 20 cycles of 94o C for 30 s, 55o C for
30 s, 68o C for 6:20 min; 68o C for 10 min.
Transformation: 2µL of the mutagenesis reaction was added to
DH5α-T1 chemically competent cells and heat shocked at 42oC
for 30 s.  200 µL SOC medium was added to the cells, and the
mixtures were incubated at 37o C for 1 hr.  Cells were plated
onto LB-ampicillin plates.  Background control cells transformed
with freshly mutated Lac-Z-containing control vector were
plated onto LB-ampicillin plates containing 0.5 mg/mL X-gal.  β-
galactosidase converts X-gal into a blue product that is easily
seen in a bacteria colony.  If the LacZ gene were mutated,
bacteria would not produce the blue product.  We determined
the efficiency of mutagenesis by determining the proportion of
colorless colonies in the control mutagenesis reaction. Over 90
% of the colonies remained colorless.  Results of the
mutagenesis were analyzed by DNA sequencing at the
University of Chicago sequencing facility.
Transformation into Yeast
Transformation: The pYes2.1 vector containing α-synuclein was
transformed into a haploid, URA-3 deficient strain of
Saccharomyces cerevisiae (TSY623: MATα ade2-101 his3-
Δ200leu2-3,112 ura3-52).  The protocol for High efficiency
transformation was followed (Burke, 2000).  5mL YEPD was
inoculated with yeast and incubated overnight at 30o C.  50 mL
YEPD was inoculated with the overnight culture to a
concentration of 5x106 cells/mL and was incubated for 4 h.
Cells were harvested, washed in sterile water, and
resuspended in 250 µL 0.1 M lithium acetate.  50 µL of the
yeast suspension was transferred to a microfuge tube.
Transformation mix (240 µL 50% w/v PEG, 36 µL 1.0M LiAc, 25
µL 2.0 mg/ml single-stranded carrier DNA, 5 µL plasmid
containing α-synuclein, 45 µL water) was added to the cell
mixture.  Cells were incubated at 30o C for 30 min, and heat-
shocked at 42o C for 20 min.  Cells were pelleted and
resuspended in 1.0 mL water.  Yeast cells were grown on
synthetic-complete media lacking in uracil (SC-URA), selecting
for yeast cells that contained the expression vector.
Whole yeast colony PCR:  Yeast colony PCR was conducted to
verify the presence of α-synuclein in the correct orientation with
the expression plasmid.  The gene was amplified once again
using the vector-specific primer GAL1 FP, the α-synuclein-
specific reverse primer,  2µL 10 x PCR buffer, 1.2µL 25 mM
MgCl2, 0.4µL 10 mM dNTPs, 15 pmol RP1, 15 pmol GAL1FP,
0.2µL Taq polymerase, and 10µL dH20 added to a small yeast
colony.  The following PCR cycle profile was used: 94o C for 4
min; 35 cycles at 94o C for 1 min, 55o C for 1 min, 72o C for 2
min; final elongation 72o C for 10 min).  The result was analyzed
by gel electrophoresis. The PCR product with an expected size
of 547 bp was analyzed by gel electrophoresis using a 1%
agarose gel.
Expression of α-Synuclein
Timecourse Expression: Since α-synuclein was subcloned next
to the Gal1 promoter in one pYES2 vector in the presence of
galactose and absence of glucose, the expression of α-
synuclein should be induced.  50 mL of SC-URA with 2%
galactose and 50 mL of SC-URA with 2% glucose (control) was
inoculated with yeast containing the expression vector to a
concentration of 5 x106 cells/mL.  5 mL of the culture was
removed at 0 h, 3h, 6h, 12h, 24 h, 36 h, and 48 h.  Cells were
counted using a hemocytometer counting chamber. 
Subsequent Expression: Expression of α -synuclein for all
further experimentation was induced in SC-URA media for 24 h.
Western Blot Analysis
Preparation of Cell Lysates:  Followed protocol of Yeast protein
extracts (Burke, 2000).  2 ml of 50 mM Tris (pH 7.5), 10 mM
NaN3 (sodium azide) was added to yeast cell pellets containing
approximately 2.5 x107 cells.  The mixture was vortexed and
repelleted in a 1.5 mL microfuge tube.  The supernatant was
pipetted from the tube.  30 µL Electrophoresis Sample Buffer
(ESB) buffer (2% SDS, 80 mM Tris (pH6.8), 10% glycerol, 1.5%
DTT, 1mg/mL bromophenol blue) containing a protease
inhibitor cocktail (1 mM PMSF, 0.7µg/mL pepstation A, 0.5
µg/mL leupeptin, 10 µg/mL E64, 2 µg/mL aprotinin) was added
to the cell pellet.  The mixture was vortexed and heated at 100o
C for 3 min.  Approximately 0.1g of 0.5 mm glass beads were
added to the cell mixture.  The microfuge tube was vortexed for
three minutes.  70 µL ESB was added, and the tube was
centrifuged for 30 s.
SDS Gel Electrophoresis and Western Transfer:  15uL of cell
homogenate was added to each lane of 4-20% SDS gel.  The
gel was run for 90 minutes at 130 volts.  Sea Blue (Invitrogen)
was used as the molecular standard.  Protein gels were
transferred to PVDF membrane (BioExpress) by
electorphoresis for 90 minutes at 30 volts.
Protein Detection: PVDF membranes were rinsed with Tris-
buffered saline (TBS) blocking buffer containing 3% Tween-20
for 30 minutes.  The membrane was incubated with 10 mL
primary antibody solution for at least one hour.  The membrane
was rinsed with TBS antibody wash solution.  The membrane
was incubated in alkaline phosphatase (AP) conjugated
secondary antibody solution for 30 minutes.  The membrane
was rinsed with TBS and deionized water.  The secondary
antibody was detected using BioRad 5-bromo-4-chloro-3-indoyl
phosphate p-toluidine salt (BCIP) and p-nitro blue tetrazolium
chloride (NBT) color developer (30 mg NBT dissolved in 1 mL
70% dimethylformamide, 15 mg BCIP dissolved in 1 mL 100%
dimethylformamide, 100 mL Tris buffer).  The membrane was
exposed to the developing solution until bands appeared (30 s-
5 min).  The reaction was quenched with several rinses of
deionized water.
Antibody Solutions: Antibodies were diluted in blocking buffer to
1x concentration.  Antibodies used: Mouse anti-V5 IgG 5000x
(Invitrogen 46-0705), used for the detection of the V5 epitope
on α-synuclein protein; Goat Anti-mouse AP-conjugated
secondary IgG 1x (Western Breeze), used to detect of Anti-V5
primary IgG; rabbit anti-RSP5 polyclonal Ab 5000x, used for the
detection of yeast house keeping protein RSP5 (gift from Linda
Hicke, Northwestern University); Mouse anti-α-synuclein
monoclonal IgG (Zymed) used to detect α-synuclein protein;
goat anti-rabbit AP-conjugated secondary IgG 2500x (Santa
Cruz biotech #6192), used to detect anti-RSP5 primary
antibody.
Protein Purification under Denatured Conditions
α-Synuclein expression was induced in galactose medium for
24 h.  Protein was purified using the Invitrogen Probond
Purification System under denaturing conditions.  A 50 mL
yeast culture was centrifuged and the supernatant was
decanted.  8 mL 6 M guanidinium lysis buffer (6 M guanidinium
HCl, 20 mM NaPO4 (pH 7.8), and 500 mM NaCl; 1 mM PMSF,
0.7µg/mL pepstation A, 0.5 µg/mL leupeptin, 10 µg/mL E64, 2
µg/mL aprotinin) was added to the cell pellet.  Cells were lysed
by vortex mixing for several minutes, and the soluble fraction
was separated by centrifugation.  The supernatant was
transferred to a column containing nickel-coated resin.  The
protein containing the poly-histidine tag was allowed to bind
over a 30 min incubation period.  The resin was allowed to
settle and the supernatant was removed.  The column was
washed with two portions of 6 mL denaturing binding buffer (8
M urea, 20mM NaPO4 (pH 7.8), 500 mM NaCl).  The column
was rinsed with two portions of 6 mL denaturing wash buffer (8
M urea, 20 mM NaPO4 (pH 7.8), 500 mM NaCl).  The column
was then washed with four portions of 8 mL native wash buffer
(containing 20 mM imidazole, pH 8.0).  500 µL of each fraction
decanted from the column was stored for western analysis.  α-
Synuclein was eluted from the column with 8 mL native elution
buffer containing (250 mM imidazole) in 1 mL fractions.
Fractions were analyzed for the presence of α-synuclein by
Western analysis just described, and α-synuclein rich fractions
were pooled, dialyzed, and concentrated.
Protein Purification Under Native Conditions
All procedures were the same as purification under denatured
conditions with the following exceptions.  Yeast cells were lysed
in native binding buffer (50 mM NaPO4, 0.5 M NaCl, 10 mM
imidazole, and 10 mM lyticase, 1 mM PMSF, 0.7µg/mL
pepstation A, 0.5 µg/mL leupeptin, 10 µg/mL E64, 2 µg/mL
aprotinin).  The cell supernatant was allowed to bind for 90 min.
The column was only washed four times with 8 mL native wash
buffer.  Protein was eluted as previously described.  An
additional step was recently tested.  1 mL concentrated cell
solutions were bead-beaten with 300 mg 0.5 mm glass beads
on a Biospec mini-beadbeater for 3 minutes at highest speed
after the addition of lysis buffer.  Bead beating had no effect on
solubilizing α-synuclein.
Protein Dialysis and Concentration
Pooled elutions fractions (6 mL) were dialyzed and
concentrated using the Tube-O-Dialyzer (786-142; Geno
Technologies).  Pooled fractions were transferred to the dialysis
tubes containing a semi-permeable membrane cap.  Samples
were placed membrane-side down in a 1000 mL beaker filled
with deionized water.  Small molecules (including purification
buffers) passively moved across the membrane.  Water was
changed 10-12 h later.  Protein samples were dialyzed for at
least 24 h.  To concentrate protein the dialysis tubes were
placed membrane-side down onto a beaker half filled with a
high molecular weight polymer that absorbed the water through
the membrane.  The membrane cap was cleaned periodically to
maximize water transfer.  Protein was then brought to 500 µL to
standardize protein concentration analysis.
Protein concentrations were determined using the
Bio-Rad Protein Assay.  5 dilutions of bovine serum albumin
(BSA; 0.0 µg/mL, 2.0 µg/mL, 4.0 µg/mL, 6.0 µg/mL, and 8.0
µg/mL) were prepared in duplicate in 800µL deionized water to
make a standard curve.  Duplicate samples of 20 µL
concentrated protein were diluted to 800 µL (40x) in deionized
water.  200 µL dye reagent concentrate (Bio-Rad 500-006) was
added to each sample.  The samples were vortexed and
incubated at room temperature for 30 min.  Absorbances for
each sample were measured at 595 nm, using the Hitachi U-
2000 spectrophotometer.  Protein concentrations were
determined from the equation of the standard curve and the 40x
dilution factor.
Differential Centrifugation
Yeast cells containing α-synuclein cDNA were grown in uracil-
lacking media containing galactose for two days.  300 µL of cell
suspension was drawn from the media and pelleted.  Cells
were bead-beaten in 1 mL deionized water for 3 min. 25 µL
ESB was added to a 100 µL sample of fresh cell lysate and a
100 µL sample of freshly purifed protein.  100 µL samples of
cell lysate and purified protein were centrifuged at 14,000 rpm
(11,000 x g) for 30 min in an Eppendorf 5415C microfuge.
Likewise, 100 µL samples of cell lysate and purified protein
were centrifuged at 111,000 x g for 30 min in a Beckman
Coullier airfuge (lab of David Mueller, Finch Medical School).
The supernatants were aspirated and added to 25 µL ESB
buffer.  The lysate pellets were resuspended in 125 µL ESB.
The presence of α-synuclein was detected in all samples by
Western analysis.
Loss of Induction
Yeast cells containing α-synuclein cDNA were grown in 50 mL
uracil-lacking media containing galactose for 24 h.  1 mL
sample of cells was drawn from the culture for Western
analysis.  The remaining cells were pelleted, washed with 0.10
M Na2PO4 buffer (pH 7.4), and repelleted.  Cells were then
resuspended in uracil-lacking media containing glucose for 24
h.  1 mL of cells was drawn from the culture for Western
analysis.  The remaining cells were pelleted, washed with 0.10
M Na2PO4 buffer (pH 7.4), and repelleted.  Cells were
resuspended in 50 mL uracil-lacking media containing glucose.
1 mL samples of cells were drawn from culture every 12 h over
the next 72 h.  Cells from each sample were counted in a
hemocytometer chamber, and equivalent amounts of cells from
each sample were prepared for Western analysis.
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